Krascendo 1 trial: Patients with previously treated advanced/metastatic KRAS G12C-altered #NSCLC, divarasib therapy improves survival outcomes compared with sotorasib or adagrasib.

CancerTherapyAdvisor· @CancerTherAdvsr · X·2026-10-27 01:40· 7 小时前评分70

正文 · 原文

Presented at #ESMO26 and published in @NEJM, read the data:
https://bit.ly/4ztZSgZ

11 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

LBA5NCT06497556按 KRASCENDO-1 对上

KRASCENDO-1

https://esmocongress.esmo.org

NCT06497556NCT06497556按 KRASCENDO-1 对上

KRASCENDO-1

https://esmocongress.esmo.org

来源：CancerTherapyAdvisor · x.com